A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
Public ClinicalTrials.gov record NCT05472090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management of multi-site pain associated with Long COVID.
Study identification
- NCT ID
- NCT05472090
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 18, 2022 (Actual)
- Primary completion
- Jul 12, 2023 (Actual)
- Completion
- Jul 27, 2023 (Actual)
- Last update posted
- Nov 26, 2024
2022 – 2023
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Accel Research-Birmingham Clinical Research Unit | Birmingham | Alabama | 35216 | — |
| Tonix Clinical Site | Oceanside | California | 92056 | — |
| Tonix Clinical Site | Santa Ana | California | 92705 | — |
| Tonix Clinical Site | Centennial | Colorado | 80112 | — |
| Tonix Clinical Site | Aventura | Florida | 33180 | — |
| Tonix Clinical Site | Fort Myers | Florida | 33912 | — |
| Tonix Clinical Site | Orlando | Florida | 32801 | — |
| Tonix Clinical Site | St. Petersburg | Florida | 33709 | — |
| Tonix Clinical Site | Alpharetta | Georgia | 30022 | — |
| Tonix Clinical Site | Atlanta | Georgia | 30329 | — |
| Tonix Clinical Site | Chicago | Illinois | 60625 | — |
| Tonix Clinical Site | Des Moines | Iowa | 50265 | — |
| Tonix Clinical Site | Iowa City | Iowa | 52242 | — |
| Tonix Clinical Site | Prairie Village | Kansas | 66208 | — |
| Tonix Clinical Site | New Orleans | Louisiana | 70124 | — |
| Tonix Clinical Site | Prairieville | Louisiana | 70769 | — |
| Tonix Clinical Site | Boston | Massachusetts | 02115 | — |
| Tonix Clinical Site | Boston | Massachusetts | 02131 | — |
| Tonix Clinical Site | Methuen | Massachusetts | 01844 | — |
| Tonix Clinical Site | Gulfport | Mississippi | 39503 | — |
| Tonix Clinical Site | Albuquerque | New Mexico | 87109 | — |
| Tonix Clinical Site | New York | New York | 10036 | — |
| Tonix Clinical Site | Williamsville | New York | 14221 | — |
| Tonix Clinical Site | Shelby | North Carolina | 28150 | — |
| Tonix Clinical Site | Columbus | Ohio | 43215 | — |
| Tonix Clinical Site | Dayton | Ohio | 45432 | — |
| Tonix Clinical Site | Tulsa | Oklahoma | 74133 | — |
| Tonix Clinical Site | Austin | Texas | 78737 | — |
| Tonix Clinical Site | McKinney | Texas | 75070 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05472090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 26, 2024 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05472090 live on ClinicalTrials.gov.